semaglutide for prediabetes Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Once-Weekly Semaglutide 2.4 mg Improved

A rat study found that at equivalent doses, sublingual semaglutide achieved significantly higher area under the curve (AUC) than oral administration: 82.53 vs 15.08 ng*h/mL

NICE guidance requires specialist initiation, specific BMI criteria, weight-related comorbidities, and treatment as part of comprehensive lifestyle programmes

Introduction Did you know that a significant percentage of patients using GLP-1 medications for weight loss may unknowingly be at risk of developing acute pancreatitis

Yes SCFAs improve mitochondrial activity, enhance fat oxidation, and strengthen metabolic flexibility

Compared to oral tirzepatide vs injectable tirzepatide, injectable options have shown reliable efficacy, offering the assurance of studies and approvals lacking in compounded oral tirzepatide formulations